Zai Lab (ZLAB) said Monday that a phase 3 clinical trial evaluating first-line bemarituzumab plus chemotherapy for the treatment of gastric cancer met its primary endpoint of overall survival at an interim analysis.
The biopharmaceutical company said the treatment combination demonstrated a "statistically significant and clinically meaningful" improvement in overall survival compared with placebo plus chemotherapy.
Zai Lab also said that a phase 3 trial of bemarituzumab plus chemotherapy and nivolumab is ongoing and that data readout is expected in H2.
Shares of Zai Lab were up 2.1% in recent early trading.
Price: 35.46, Change: +0.71, Percent Change: +2.06
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。